


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C07K 16/42, 16/24, C12N 15/19, 15/66	A3	(11) International Publication Number: WO 00/09560 (43) International Publication Date: 24 February 2000 (24.02.00)
(21) International Application Number: PCT/US99/18777		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 17 August 1999 (17.08.99)		
(30) Priority Data: 60/096,868 17 August 1998 (17.08.98) US		
(71) Applicant: ABGENIX, INC. [US/US]; 7601 Dumbarton Circle, Fremont, CA 94555 (US).		
(72) Inventors: GALLO, Michael; 1376 Klamath Drive, San Jose, CA 95130 (US). JUNGHANS, Richard; 47 Rutland Square #3, Boston, MA 02118 (US). FOORD, Orit; 804 Cortez Lane, Foster City, CA 94404 (US).		Published <i>With international search report.</i>
(74) Agents: HALEY, James, F. et al.; Fish & Neave, 1251 Avenue of the Americas, New York, NY 10020 (US).		(88) Date of publication of the international search report: 18 May 2000 (18.05.00)

(54) Title: GENERATION OF MODIFIED MOLECULES WITH INCREASED SERUM HALF-LIVES

(57) Abstract

In accordance with the present invention, there are provided methods for the extension of serum half-lives of proteinaceous molecules, particularly antibody molecules, and compositions of molecules modified in accordance with the methods of the invention. In accordance with a first aspect of the present invention, there is provided a method of modifying the half-life of an antibody through providing an antibody containing an FcRn binding domain or the genes encoding such antibody and physically linking the antibody or the antibody as encoded to a second FcRn binding domain. In accordance with a second aspect of the present invention, there is provided a molecule that contains at least two distinct FcRn binding moieties.

Competition for binding with protein AHRP

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

UNIVERSAL SEARCH REPORT

Application No

PCT/US 99/18777

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K16/42 C07K16/24 C12N15/19 C12N15/66

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 97 34631 A (UNIV TEXAS ;WARD ELIZABETH SALLY (US)) 25 September 1997 (1997-09-25) cited in the application page 3, line 4-19 page 4, line 9 -page 20, line 11 page 25, line 20 -page 47, line 13	1-11
Y	EP 0 770 628 A (CHUGAI PHARMACEUTICAL CO LTD) 2 May 1997 (1997-05-02) page 3, line 41 page 9, line 11 -page 18, line 26; example 5	1-11
	— —/— <i>Human IgG1 X-IL-8</i> <i>"Recombinant human antibody specific</i> <i>human IL-8"</i>	

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the International filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the International filing date but later than the priority date claimed

"T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the International search

Date of mailing of the International search report

15 February 2000

28/02/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Mateo Rosell, A.M.

BEST AVAILABLE COPY

INTERNATIONAL SEARCH REPORT

Application No
PCT/US 99/18777

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 97 43316 A (BETH ISRAEL HOSPITAL) 20 November 1997 (1997-11-20) cited in the application page 5, line 6-12 page 7, line 19 -page 8, line 14 page 11, line 25 -page 12, line 22; examples I-IV	1,7,10, 11
A	WO 96 32478 A (GENENTECH INC) 17 October 1996 (1996-10-17) cited in the application page 10, line 1-31	1,4
A	WO 98 31820 A (BORYUNG PHARM ;CHUNG YONG HOON (KR)) 23 July 1998 (1998-07-23) abstract page 2, line 9-20; figures 3,4	1,3,10, 11
A	WO 94 04689 A (US HEALTH) 3 March 1994 (1994-03-03) abstract page 3, line 35 -page 4, line 15 page 11, line 1414 -page 41; example 1	1,4
A	KIM J-K ET AL., : "Localization of the site of the murine IgG1 molecule that is involved in binding to the murine intestinal Fc receptor" EUROPEAN JOURNAL OF IMMUNOLOGY , vol. 24 (10), 1994, page 2429-2434 XP000878770 the whole document	1,4
A	GHETIE V ET AL., : "Increasing the serum persistence of an IgG fragment by random mutagenesis." NATURE BIOTECHNOLOGY, vol. 15 (7), 1997, page 637-640 XP000876642 the whole document	1,4
A	KIM J -K ET AL: "IDENTIFYING AMINO ACID RESIDUES THAT INFLUENCE PLASMA CLEARANCE OF MURINE IgG1 FRAGMENTS BY SITE-DIRECTED MUTAGENESIS" EUROPEAN JOURNAL OF IMMUNOLOGY, DE, WEINHEIM, vol. 24, no. 3, 1994, page 542-548 XP000590871 ISSN: 0014-2980 cited in the application the whole document	1,4

INTERNATIONAL SEARCH REPORT

Information on patent family members

1st Application No

PCT/US 99/18777

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 9734631	A	25-09-1997	AU	1985097 A	10-10-1997
			CA	2249195 A	25-09-1997
			EP	0904107 A	31-03-1999
EP 0770628	A	02-05-1997	AU	701342 B	28-01-1999
			AU	2936395 A	16-02-1996
			US	5994524 A	30-11-1999
			CA	2194907 A	01-02-1996
			HU	77420 A	28-04-1998
			WO	9602576 A	01-02-1996
			JP	8217799 A	27-08-1996
			ZA	9505832 A	10-04-1996
WO 9743316	A	20-11-1997	NONE		
WO 9632478	A	17-10-1996	AU	5435996 A	30-10-1996
			BR	9604955 A	09-06-1998
			CA	2217871 A	17-10-1996
			CN	1186517 A	01-07-1998
			EP	0821732 A	04-02-1998
			JP	11504509 T	27-04-1999
WO 9831820	A	23-07-1998	AU	5681498 A	07-08-1998
WO 9404689	A	03-03-1994	AU	5098393 A	15-03-1994

BEST AVAILABLE COPY

THIS PAGE BLANK (USPTO)